These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31072635)

  • 21. Echocardiography in pediatric pulmonary arterial hypertension: early study on assessing disease severity and predicting outcome.
    Ploegstra MJ; Roofthooft MT; Douwes JM; Bartelds B; Elzenga NJ; van de Weerd D; Hillege HL; Berger RM
    Circ Cardiovasc Imaging; 2015 Jan; 8(1):. PubMed ID: 25552488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines.
    Dardi F; Manes A; Guarino D; Zuffa E; De Lorenzis A; Magnani I; Rotunno M; Ballerini A; Lo Russo GV; Nardi E; Galiè N; Palazzini M
    Open Heart; 2021 Oct; 8(2):. PubMed ID: 34667092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Balloon atrial septostomy in pulmonary arterial hypertension: effect on survival and associated outcomes.
    Chiu JS; Zuckerman WA; Turner ME; Richmond ME; Kerstein D; Krishnan U; Torres A; Vincent JA; Rosenzweig EB
    J Heart Lung Transplant; 2015 Mar; 34(3):376-80. PubMed ID: 25813766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk stratification, prognosis, and survival in a pulmonary arterial hypertension cohort in Latin America. A multicenter study.
    Diez M; Cáneva J; Diez A; Perna ER; Aimone D; Bosio M; Márquez LL; Brasca DG; Vulcano N; Daghero F; Burgos LM; Favaloro L; Escalante JP; Coronel ML; Fernández A; Chávez Á; Secco L;
    Respir Med Res; 2023 Jun; 83():100945. PubMed ID: 36563553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five-Year outcomes of patients enrolled in the REVEAL Registry.
    Farber HW; Miller DP; Poms AD; Badesch DB; Frost AE; Muros-Le Rouzic E; Romero AJ; Benton WW; Elliott CG; McGoon MD; Benza RL
    Chest; 2015 Oct; 148(4):1043-54. PubMed ID: 26066077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency and prognostic significance of hemoptysis in pediatric pulmonary arterial hypertension.
    Roofthooft MT; Douwes JM; Vrijlandt EJ; Berger RM
    Am J Cardiol; 2013 Nov; 112(9):1505-9. PubMed ID: 23972345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Right Heart Score for Predicting Outcome in Idiopathic, Familial, or Drug- and Toxin-Associated Pulmonary Arterial Hypertension.
    Haddad F; Spruijt OA; Denault AY; Mercier O; Brunner N; Furman D; Fadel E; Bogaard HJ; Schnittger I; Vrtovec B; Wu JC; de Jesus Perez V; Vonk-Noordegraaf A; Zamanian RT
    JACC Cardiovasc Imaging; 2015 Jun; 8(6):627-38. PubMed ID: 25981508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heart rate recovery in 1 minute after the 6-minute walk test predicts adverse outcomes in pulmonary arterial hypertension.
    Rezende CF; Mancuzo EV; Corrêa RA
    PLoS One; 2022; 17(5):e0268839. PubMed ID: 35622825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension).
    Beghetti M; Schulze-Neick I; Berger RM; Ivy DD; Bonnet D; Weintraub RG; Saji T; Yung D; Mallory GB; Geiger R; Berger JT; Barst RJ; Humpl T;
    Int J Cardiol; 2016 Jan; 203():325-30. PubMed ID: 26583838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival.
    Sajan I; Manlhiot C; Reyes J; McCrindle BW; Humpl T; Friedberg MK
    Am Heart J; 2011 Sep; 162(3):562-8. PubMed ID: 21884877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary arterial hypertension in a multi-ethnic Asian population: Characteristics, survival and mortality predictors from a 14-year follow-up study.
    Lim Y; Low TT; Chan SP; Teo TW; Jang JJ; Yip N; Kuntjoro I; Tay EL; Yip JW
    Respirology; 2019 Feb; 24(2):162-170. PubMed ID: 30180305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial.
    Fauvel C; Liu Y; Correa-Jaque P; Kanwar MK; Vizza CD; Lin S; Benza RL
    Chest; 2023 Dec; 164(6):1518-1530. PubMed ID: 37356711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute Vasodilator Response in Pediatric Pulmonary Arterial Hypertension: Current Clinical Practice From the TOPP Registry.
    Douwes JM; Humpl T; Bonnet D; Beghetti M; Ivy DD; Berger RM;
    J Am Coll Cardiol; 2016 Mar; 67(11):1312-23. PubMed ID: 26988953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk classification of pulmonary arterial hypertension by echocardiographic combined assessment of pulmonary vascular resistance and right ventricular function.
    Kawamukai M; Hashimoto A; Koyama M; Nagano N; Nishida J; Mochizuki A; Kouzu H; Muranaka A; Kokubu N; Nagahara D; Yuda S; Tsuchihashi K; Miura T
    Heart Vessels; 2019 Nov; 34(11):1789-1800. PubMed ID: 31119378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Active right atrial emptying fraction predicts reduced survival and increased adverse events in childhood pulmonary arterial hypertension.
    Kumar S; Vadlamudi K; Kaddoura T; Bobhate P; Goot BH; Elgendi M; Jain S; Colen T; Khoo NS; Adatia I
    Int J Cardiol; 2018 Nov; 271():306-311. PubMed ID: 30223361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry.
    Zelniker TA; Huscher D; Vonk-Noordegraaf A; Ewert R; Lange TJ; Klose H; Dumitrescu D; Halank M; Held M; Gall H; Pittrow D; Hoeper MM; Frankenstein L
    Clin Res Cardiol; 2018 Jun; 107(6):460-470. PubMed ID: 29368137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Tremblay É; Gosselin C; Mai V; Lajoie AC; Kilo R; Weatherald J; Lacasse Y; Bonnet S; Lega JC; Provencher S
    Circulation; 2022 Aug; 146(8):597-612. PubMed ID: 35862151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy.
    D'Alto M; Romeo E; Argiento P; Santoro G; Sarubbi B; Gaio G; Mélot C; Russo MG; Naeije R; Calabrò R
    Heart; 2010 Sep; 96(18):1475-9. PubMed ID: 20668108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension.
    White RJ; Vonk-Noordegraaf A; Rosenkranz S; Oudiz RJ; McLaughlin VV; Hoeper MM; Grünig E; Ghofrani HA; Chakinala MM; Barberà JA; Blair C; Langley J; Frost AE
    Respir Res; 2019 Sep; 20(1):208. PubMed ID: 31511080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening.
    Griffiths M; Yang J; Simpson CE; Vaidya D; Nies M; Brandal S; Damico R; Ivy DD; Austin ED; Pauciulo MW; Lutz KA; Rosenzweig EB; Hirsch R; Yung D; Nichols WC; Everett AD
    Chest; 2021 Jul; 160(1):297-306. PubMed ID: 33609516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.